MSDC-0160 10mg | Purity Not Available
Selleck Chemicals
MSDC-0160 (CAY10415) is a prototype mTOT-modulating insulin sensitizer being studied to treat diabetes and Alzheimer’s disease. Phase 2.
More Information Supplier PageMSDC-0160 (CAY10415) is a prototype mTOT-modulating insulin sensitizer being studied to treat diabetes and Alzheimer’s disease. Phase 2.
More Information Supplier PageXEN445 is a potent and selective endothelial lipase inhibitor with IC50 of 0.237 μM.
More Information Supplier PageLDC000067 (LDC067) is a highly selective CDK9 inhibitor with IC50 of 44 nM, 55/125/210/ >227/ >227-fold selectivity over CDK2/1/4/6/7.
More Information Supplier PageLDC000067 (LDC067) is a highly selective CDK9 inhibitor with IC50 of 44 nM, 55/125/210/ >227/ >227-fold selectivity over CDK2/1/4/6/7.
More Information Supplier PageME0328 is a potent and selective PARP inhibitor with IC50 of 0.89 μM for PARP3, about 7-fold selectivity over PARP1.
More Information Supplier PageWS3 is a β cell proliferation inducer via modulation of Erb3 binding protein-1 (EBP1) and the IκB kinase pathway.
More Information Supplier PageWS6 is a β cell proliferation inducer via modulation of Erb3 binding protein-1 (EBP1) and the IκB kinase pathway.
More Information Supplier PageZLN005 is a potent and tissue-specific PGC-1α transcriptional activator.
More Information Supplier Page